Comparison of HDAC inhibitors in clinical development Effect on HIV production in latently infected cells and T-cell activation
Thomas Aagaard Rasmussen, Ole Schmeltz Sogaard, Christel Brinkmann, Fiona Wightman, Sharon R Lewin, Jesper Melchjorsen, Charles Dinarello, Lars Ostergaard, Martin Tolstrup
Human Vaccines & Immunotherapeutics | TAYLOR & FRANCIS INC | Published : 2013
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
The Aids Foundation, Denmark; The Institute of Clinical Medicine, Aarhus University; and The Hede Nielsen Foundation, Denmark, funded the study. Italfarmaco S.p.A. delivered ITF2357 (givinostat) free of charge for use in this study. S. L. has received institutional research grants from Merck, Gilead and Janssen and has received institutional payment for lectures/educational services from Gilead, Viiv and Merck. L.O. has received consultancy and speaker's fee from: Abbott, MSD, Pfizer, Bristol-Meyer Squibb, GlaxoSmithKline, ViiV Healthcare, Gilead and Tibotec. For the remaining authors, no conflicts of interest were declared.